Pancreatic Cancer Screening: Who and How

Broadcast from KSQD, Santa Cruz on 11-06-2025:>/p>

• Dr. Dawn interviews Cindy Jackonette and Dr. Michael Alexander about a fundraiser for pancreatic cancer awareness on November 15th at Bargetto Winery from 2-5pm, supporting the Santa Cruz Cancer Benefit Group. Dr. Alexander explains pancreatic cancer has only 10-15% five-year survival rates and is difficult to screen for. Screening involves complex endoscopy procedures examining pancreatic ducts, CT scans and biomarker scans. The disease represents 3% of cancer cases but 8% of deaths. Immune checkpoint inhibitors show limited success except in Lynch syndrome patients with DNA repair defects. The Santa Cruz Cancer Benefit Group donates annually to local cancer organizations and is all volunteer-run with minimal overhead.
• An emailer asks when her 56-year-old half-African American son should get colon cancer screening given his father and uncle both had the disease. Dr. Dawn explains African Americans have increased risk and recommends immediate colonoscopy despite the ideal screening window being 10 years ago. She emphasizes identifying whether he produces polyps, which would require surveillance every 3-5 years. Unlike pancreatic cancer, colon cancer is highly curable when detected early, with death rates dropping 30-40% since colonoscopies became standard in the mid-1990s. She recommends preventive measures including daily 200mg ibuprofen (if no ulcer history) and a high-fiber diet rich in colorful vegetables containing antioxidants that reduce oxidative stress and DNA damage from free radicals.
• An emailer from Israel asks about supporting his 38-year-old son's rectal adenocarcinoma treatment. Dr. Dawn recommends nutritional strategies including juicing 10 different fruits and vegetables daily, 20mg melatonin for synergy with chemotherapy, vitamin D supplementation, and L-glutamine as primary food for bowel healing and lymphocyte function. She suggests DHA fish oil to enhance chemotherapy effectiveness, green tea for oncogene inhibition, astragalus herb to increase phagocytic activity and natural killer cells, and rotating water-extracted mushroom formulas with beta-glucans, particularly maitake and shitake. Glutamine also protects mucous membranes from radiation burns.
• Dr. Dawn discusses alarming cancer rate increases among young adults in Corn Belt states including Iowa, Nebraska, Illinois, Minnesota, Indiana, and Kansas. Since 2015, these states show 5% higher cancer rates for ages 15-49 compared to national averages, with particularly elevated kidney and skin cancer rates. Young women face 66% higher skin cancer risk than peers in other states. . Governor Kim Reynolds invested $1 million for research while Bayer's attempt to shield Roundup from lawsuits failed. Dr. Dawn notes Roundup now contains diquat after removing glyphosate. It has taken decades to accumulate evidence of glyphosates harms, She warns that absence of evidence of Diquats being harmful isn't evidence of safety and that Ames testing suggests high mutation potential.
• An emailer shares a JAMA article on lithium for Alzheimer's disease. Dr. Dawn explains that calcium dysregulation through NMDA receptors plays an upstream role in Alzheimer's pathology. Lithium, a bipolar disorder treatment, can reset deranged calcium gates, inhibiting mitochondrial damage and tau protein production. She emphasizes tau protein as the true culprit in Alzheimer's while amyloid beta is more symptomatic. Correcting calcium homeostasis allows neuronal autophagy systems to clear waste more efficiently rather than being overwhelmed.
• She reports dramatic peanut allergy declines following 2017 pediatric recommendations for introducing peanuts at 4-6 months based on the LEAP study showing 81% reduction. Between 2017-2020, peanut allergies dropped from 0.79% to 0.45% of all children under 3, with overall food allergies declining 36%. Studies also show pregnant mothers eating peanuts reduces offspring allergy risk by promoting immune tolerance.
• We conclude with breakthrough wireless retinal implants for macular degeneration, where cameras on glasses convert images to near-infrared signals to retinal implants which stimulate surviving retinal neurons. The prototype allowed patients to improve by two lines on eye charts and perceive facial expressions and read smaller print.